Regeneron is set to report earnings this Thursday before the bell. Analysts expect revenue to grow 3.8% year on year, in line with the 3.6% increase recorded in the same quarter last year. The company beat revenue expectations last quarter, reporting $3.61 billion, up 19% year on year. Regeneron rarely misses Wall Street revenue estimates, and analysts have generally reconfirmed their estimates over the last 30 days. The stock is up 10.1% over the last month, heading into earnings with an average analyst price target of $819.25 compared to the current share price of $695.88.
Regeneron Pharmaceuticals IncEarnings report expected with 3.8% revenue growth, but no actual results yet; stock up 10.1% ahead of report.